ライフサイエンスコーパス: deoxyuridine

1 ) lung macrophages incorporated 5-ethynyl-2'-deoxyuridine.

2 h intraperitoneal injections of 5-ethynyl-2'-deoxyuridine.

3 for 2'-deoxyuridine and 5-(hydroxymethyl)-2'-deoxyuridine.

4 the folate-deficient diet supplemented with deoxyuridine.

5 o degraded intracellularly to 5-radioiodo-2'-deoxyuridine 1 and its monophosphate 20, respectively, w

6 rboxy-2'-deoxycytidine, 5-(hydroxymethyl)-2'-deoxyuridine, 2'-deoxyuridine, and 8-oxo-2'-deoxyguanosi

7 chemistries associated with inflammation: 2'-deoxyuridine, 2'-deoxyxanthosine and 2'-deoxyinosine fro

8 of 3-N-benzoyl-3',5'-di-O-benzoyl-5-iodo-2'-deoxyuridine (2a) and 3-N-benzoyl-3',5'-di-O-benzoyl-5-i

9 F-2dUrd), and hexadecyloxypropyl 5-fluoro-2'-deoxyuridine 5'-monophosphate (HDP-P-5-F-2dUrd) were syn

10 betamethason phosphate, FdUMP = 5'-fluoro-2'-deoxyuridine 5'-monophosphate).

11 rminal deoxynucleotidyl transferase-mediated deoxyuridine 5-triphospate nick end labeling).

12 vFLIP, can metabolize the prodrug 5-fluoro-5-deoxyuridine (5-dFUrd) to 5-fluouridine (5-FU), a potent

13 by measuring nucleotide analog 5-ethynyl-2'-deoxyuridine (5-EdU) incorporation into the DNA and isle

14 abinofuranosylguanine (AraG) and 5-fluoro-2'-deoxyuridine (5-F-2dUrd).

15 cally deaminated to yield 5-hydroxymethyl-2'-deoxyuridine (5-HmdU).

16 Terminal deoxynucleotidyl transferase 2'-Deoxyuridine, 5'-Triphosphate nick end labeling and p65

17 of terminal deoxynucleotidyl transferase 2'-deoxyuridine, 5'-triphosphate nick end labeling staining

18 ted for the terminal transferase-mediated 2'-deoxyuridine, 5'-triphosphate nick end-labeling assay an

19 and terminal deoxynucleotidyl transferase 2-deoxyuridine, 5-triphosphate nick end-labeling analyses

20 containing the VZ were exposed to 5-bromo-2'-deoxyuridine-5'-monophosphate (BrdU) in vitro.

21 5) catalyzes the reductive methylation of 2'-deoxyuridine-5'-monophosphate (dUMP) by N(5),N(10)-methy

22 its complex with Escherichia coli TS and 2'-deoxyuridine-5'-monophosphate, and a model for a similar

23 e the methylation of the uracil moiety of 2'-deoxyuridine-5'-monophosphate.

24 ve site residue of the enzyme to activate 2'-deoxyuridine-5'-monophosphate.

25 ed to the antivirals (E)-5-(2-bromovinyl)-2'-deoxyuridine (5BVdU) and alpha interferon (IFN-alpha) an

26 5% of thymidine (T) with 5'-hydroxymethyl-2'-deoxyuridine (5hmU) in the Escherichia coli genome.

27 -(17beta-succinyl-5alpha-androstan-3-one)-2'-deoxyuridine 8 and 5-radioiodo-3'-O-(17beta-succinyl-5al

28 starting from acetyl-protected 5-alkynyl-2'-deoxyuridines (85-86%).

29 EdU (ethynyl deoxyuridine, a thymidine analog) and annexin-propidium

30 Using 5-bromo-2-deoxyuridine administration at P2, P11, P22, or P120-P12

31 ficiently and had a 5-fold reduced thymidine/deoxyuridine affinity.

32 ethanesulfonate (MMS) and 5-hydroxymethyl-2'-deoxyuridine, agents that introduce base excision repair

33 5-(Thien-2-yl)-2'-deoxyuridine, an isomorphic fluorescent nucleoside analo

34 This deoxyuridine analog also displays a mega-Stokes shift, w

35 oligodeoxynucleotides (ODNs) of an emissive deoxyuridine analog electronically conjugated on its C5-

36 When incorporated in ODNs, this fluorescent deoxyuridine analog exhibits remarkable photostability a

37 ther nucleotides, including 5-substituted 2'-deoxyuridine analogs, once they have been flipped from t

38 No such differences was found for 2'-deoxyuridine and 5-(hydroxymethyl)-2'-deoxyuridine.

39 5-ethynyl-2'-deoxyuridine and 5-bromo-2'-deoxyuridine incorporation a

40 Once again, only 5-hydroxymethyl-2'-deoxyuridine and 5-hydroxymethyl-2'-deoxycytidine are pr

41 re because only compounds 5-hydroxymethyl-2'-deoxyuridine and 5-hydroxymethyl-2'-deoxycytidine were f

42 hat two of our compounds, 5-hydroxymethyl-2'-deoxyuridine and 5-hydroxymethyl-2'-deoxycytidine, shoul

43 Sequential administration of 5-chloro-2-deoxyuridine and 5-iodo-2-deoxyuridine indicated that al

44 h BSM cell proliferation by using 5-bromo-2'-deoxyuridine and cell counting and in the expression of

45 saturated pyrimidine lesions, 5,6-dihydro-2'-deoxyuridine and pyrimidine (6-4) pyrimidone photoproduc

46 bovine uridine phosphorylase treated with 2'-deoxyuridine and sulfate show intact nucleoside.

47 e natural pyrimidine nucleosides uridine, 2'-deoxyuridine and thymidine inhibited mycoplasma-associat

48 In contrast, in undamaged 2'-deoxyuridine and thymidine, reactions at elevated temper

49 with similar specificity for uridine and 2'-deoxyuridine and undetectable activity toward thymidine

50 ansporter had low affinity for uridine and 2'deoxyuridine and was the sole pyrimidine transporter exp

51 ardiomyocytes demonstrated EdU (5-ethynyl-2'-deoxyuridine) and phosphorylated histone H3 positivity i

52 idine, 5-(hydroxymethyl)-2'-deoxyuridine, 2'-deoxyuridine, and 8-oxo-2'-deoxyguanosine.

53 acillus subtilis P RNA with 4-thiouridine, 4-deoxyuridine, and abasic modifications and G378/379 with

54 e knockout mice with exogenous thymidine and deoxyuridine, and assessed clinical, neuroradiological,

55 e assessed by labeling cells with 5-bromo-2'-deoxyuridine, and fecal microbial community composition

56 Elevated plasma and urine thymidine and deoxyuridine, and genetic testing for TYMP variants, con

57 yribose was synthesized using carbocyclic 2'-deoxyuridine as starting material.

58 Cs within the myocardium, whereas 5-bromo-2'-deoxyuridine assays revealed de novo in vivo cardiomyocy

59 -induced deaminase converts deoxycytidine to deoxyuridine at the Ig loci.

60 antibodies and the other using a 5-ethynyl-2-deoxyuridine-based chemical reaction, only after the eme

61 Using 5-bromo-2-deoxyuridine birthdating to identify newborn cells, we f

62 FP to tag the newborn rods and by 5-bromo-2'-deoxyuridine birthdating, we demonstrate that early-born

63 itions and either 5-(N-benzylcarboxamide)-2'-deoxyuridine (Bn-dU) or 5-[N-(1-naphthylmethyl)carboxami

64 Treatment of cultured cells with 5-bromo-2'-deoxyuridine ((Br)dU) is known to result in the substitu

65 metazoans in response to analogs 5-bromo-2'-deoxyuridine (BrdU) and 5-ethynyl-2'-deoxyuridine (EdU).

66 Systemic injections of 5-bromo-2'-deoxyuridine (BrdU) and intraventricular injections of r

67 We used 5'-bromo-2'-deoxyuridine (BrdU) and retroviral methodologies to birt

68 labeled with the nucleotide analog 5-bromo-2-deoxyuridine (BrdU) and sorted into S-phase fractions on

69 transected and injected with 5-bromo-2&prime-deoxyuridine (BrdU) at 0-3 weeks posttransection.

70 gions by injecting quail eggs with 5-bromo-2-deoxyuridine (BrdU) at various stages between embryonic

71 beled by subretinal injection of 5'-bromo-2'-deoxyuridine (BrdU) followed by immunohistochemistry.

72 5-Bromo-2'-deoxyuridine (BrdU) has been investigated as a radiosens

73 peritoneally (IP) with 50 mg/kg of 5-bromo-2-deoxyuridine (BrdU) immediately after anesthesia.

74 was measured by administration of 5-bromo-2'-deoxyuridine (BrdU) in the drinking water.

75 Mice were then given pulses of 5-bromo-2'-deoxyuridine (BrdU) in their drinking water, followed by

76 es in [methyl-(3)H] thymidine and 5-bromo-2'-deoxyuridine (BrdU) incorporation and in the number of c

77 SisterC employs 5-bromo-2'-deoxyuridine (BrdU) incorporation during S-phase to labe

78 Using 5-Bromo-2'-deoxyuridine (BrdU) incorporation to generate genome-wid

79 hrough flow cytometric analysis of 5-bromo-2'deoxyuridine (BrdU) incorporation.

80 le Macaca fascicularis) were given 5-bromo-2-deoxyuridine (BrdU) injections 2-3 weeks after the rhizo

81 hether a single administration of 5-bromo-2'-deoxyuridine (BrdU) interferes with cell proliferation a

82 Monocyte progenitors were 5-bromo-2'-deoxyuridine (BrdU) labeled in bone marrow, and CNS macr

83 Mathematical modeling of 5-bromo-2' deoxyuridine (BrdU) labeling dynamics demonstrated a sig

84 determined using ImageJ software, and bromo-deoxyuridine (BrdU) labeling was used to visualize proli

85 incorporation of new nuclei using 5-bromo-2-deoxyuridine (BrdU) labelling by isolating individual my

86 the bone marrow to the DRGs using 5-bromo-2-deoxyuridine (BrdU) pulse, and serially measured IENFD.

87 Using these models, along with a 5-bromo-2'-deoxyuridine (BrdU) pulse-label strategy, we compared me

88 lyzed the cell cycle change using 5-bromo-2'-deoxyuridine (BrdU) pulse-labeling and DAPI (4',6-diamid

89 ith the "gold standard" method of 5-bromo-2'-deoxyuridine (BrdU) staining using two behavioral paradi

90 We used 5-bromo-2'-deoxyuridine (BrdU) to identify and localize proliferati

91 one intraperitoneal injection of 5-bromo-2'-deoxyuridine (BrdU) to label progenitors in the hippocam

92 Proliferation was quantified by 5-bromo-2'-deoxyuridine (BrdU) uptake (10 mum).

93 The S-phase mitotic marker 5'-bromo-2'-deoxyuridine (BrdU) was administered at the conclusion o

94 By using 5-bromo-2'-deoxyuridine (BrdU), a label-retaining cell population w

95 Nucleoside 5-bromo-2'-deoxyuridine (BrdU), after being incorporated into cellu

96 ocytes are typically labeled with 5-bromo-2'-deoxyuridine (BrdU), deuterium, or the fluorescent dye c

97 osed to retain DNA labels, such as 5-bromo-2-deoxyuridine (BrdU), either because they segregate chrom

98 opulations are pulse-labeled with 5-bromo-2'-deoxyuridine (BrdU), fractionated according to cell-cycl

99 OP3-4 enhanced the BMP-2-induced 5-bromo-2'-deoxyuridine (BrdU)-positive cell numbers at the injecte

100 of the marker of DNA replication 5-bromo-2'-deoxyuridine (BrdU).

101 animals also received intravenous 5-bromo-2-deoxyuridine (BrdU).

102 rain of an anuran amphibian using 5-bromo-2'-deoxyuridine (BrdU).

103 oliferation, the exogenous marker 5-bromo-2'-deoxyuridine (BrdU, 200mg/kg, ip) was administered 2h in

104 5-Bromo-2-deoxyuridine (BrdU, 50 mg/kg) was intraperitoneally deli

105 both the neuronal marker NeuN and 5-bromo-2'-deoxyuridine (BrdU; a marker for proliferating cells) in

106 rs for tumor proliferation (Ki67, 5-bromo-2'-deoxyuridine [BrdU]) and cell death (caspase-3, terminal

107 ences in (a) cell proliferation (5'-bromo-2'-deoxyuridine [BrdU]), (b) neural precursor (nestin), (c)

108 or control treatments, followed by 5-bromo-2-deoxyuridine (BrdUrd) in drinking water for four weeks b

109 5-Bromo-2-deoxyuridine (BrdUrd) was administered to tumor-bearing

110 The removal of the interfering deoxyuridine by UNG, however, activated the DNAzyme.

111 miR-294 hearts showed increased 5-ethynyl-2'-deoxyuridine+ cells and upregulation of cell cycle marke

112 We confirmed using 5-ethynyl-2'-deoxyuridine click chemistry that the Oc-Cre lineage inc

113 lies on the four building blocks 5-chloro-2'-deoxyuridine (ClU), A, C and G instead of the standard T

114 1'-Cyano-2'-deoxyuridine (CNdU) and related molecules may prove usef

115 1'-Cyano-2'-deoxyuridine (CNdU) is a nanomolar competitive inhibitor

116 esulting from APOBEC activity are avoided by deoxyuridine conversion to abasic sites ahead of nascent

117 We observed that deoxyuridine could abrogate ROS-induced ER stress to pro

118 table lipid prodrugs of AraG and 5-fluoro-2'-deoxyuridine could be long-lasting, slow-release, antipr

119 (HDP-P-AraG), hexadecyloxypropyl 5-fluoro-2'-deoxyuridine cyclic 3',5'-monophosphate (HDP-cP-5-F-2dUr

120 f the oxygen in the 5,6-dihydro-6-hydroxy-2'-deoxyuridine derived from 2.

121 es in two pyrimidine lesions: 5,6-dihydro-2'-deoxyuridine (dHdU) and 5,6-dihydrothymidine (dHT), form

122 spore photoproduct" (SP), and 5,6-dihydro-2'-deoxyuridine (dHdU), formed via ionizing radiation damag

123 trypanocidal activity; 5F-orotic acid, 5F-2'deoxyuridine displayed activity in the low micromolar ra

124 nucleotide analogue 5-dimethylaminopropargyl deoxyuridine (DMAPdU) in place of thymidine and examined

125 repair of a site-specifically positioned 2'-deoxyuridine (dU) residue by uracil DNA glycosylase (UDG

126 To generate target molecules, a single deoxyuridine (dU) residue is placed 6-10 nt away from th

127 th propidium iodide (PI) and/or 5-ethynyl-2'-deoxyuridine (EdU) (S-phase label) and imaged by confoca

128 e the deoxypyrimidine analogues 5-ethynyl-2'-deoxyuridine (EdU) and 5-ethynyl-2'-deoxycytidine (EdC).

129 , based on the incorporation of 5-ethynyl-2'-deoxyuridine (EdU) and its subsequent detection by a flu

130 incorporation and detection of 5-ethynyl-2'-deoxyuridine (EdU) in fission yeast, a thymidine analogu

131 ing "click chemistry" to detect 5-ethynyl-2'-deoxyuridine (EdU) incorporation into replicating viral

132 ex, macrophage DNA content, and 5-ethynyl-2'-deoxyuridine (EdU) incorporation such that it was possib

133 and migration was evaluated by 5-ethynyl-2'-deoxyuridine (EdU) incorporation, cell count, and Boyden

134 ew perspective, we incorporated 5-ethynyl-2'-deoxyuridine (EdU) into nascent DNA in cells infected wi

135 abeling of the thymidine analog 5-ethynyl-2'-deoxyuridine (EdU) into nascent viral DNA during cellula

136 Based on cumulative 5-ethynyl-2'-deoxyuridine (EdU) labeling as well as Ki67 and prolifer

137 We combined 5-ethynynl-2'-deoxyuridine (EdU) labeling with antibody markers that i

138 (aPC) and used prelabeling with 5-ethynyl-2'-deoxyuridine (EdU) to assess cell proliferation.

139 eling of proliferating cells by 5-ethynyl-2'-deoxyuridine (EdU) to profile individual dividing cells.

140 d based on the incorporation of 5-ethynyl-2'-deoxyuridine (EdU), a thymidine analogue, into cellular

141 n-1 (Magp1) in conjunction with 5-ethynyl-2'-deoxyuridine (EdU), an S-phase marker.

142 elutriation, labeled cells with 5-ethynyl-2'-deoxyuridine (EdU), and then treated each population wit

143 5-ethynyl-2'deoxyuridine (EdU)-a thymidine analog-containing minipum

144 Following adoptive transfer of 5-ethynyl-2'-deoxyuridine (EdU)-labeled hemocytes, labeled cells popu

145 microscopic analyses involving 5-ethynyl-2'-deoxyuridine (EdU)-labeled pseudogenomes and antibodies

146 romo-2'-deoxyuridine (BrdU) and 5-ethynyl-2'-deoxyuridine (EdU).

147 DNA with the nucleoside analog 5-ethynyl-2'-deoxyuridine (EdU).

148 stomorphometry, using Ki-67 and 5-ethynyl-2'-deoxyuridine (EdU).

149 NAs were designed that contained 5-fluoro-2'-deoxyuridine (FdU) moieties at various locations within

150 The antitumor drug 5-fluoro-2'-deoxyuridine (FdUrd) also sensitizes tumor cells to ioni

151 Catalytic reduction (5% Rh/alumina) of 2'-deoxyuridine, followed by reduction with sodium borohydr

152 Animals received 5-bromo-2-deoxyuridine for 6 days.

153 Two novel series of 5-fluoroalkyl-2'-deoxyuridines (FPrDU, FBuDU, FPeDU) and 2'-fluoro-2'-deo

154 tary thymidine and serine enhance 5-fluoro 2'deoxyuridine (FUdR) toxicity in C. elegans through diffe

155 ic drugs: 5-fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FUDR), and camptothecin (CPT).

156 t a novel mechanism for error-free bypass of deoxyuridines generated within ssDNA and suggest that th

157 order of catalytic efficiencies: thymidine > deoxyuridine >> deoxyinosine > deoxyguanosine.

158 or deamination of hmdC to 5-hydroxymethyl-2'-deoxyuridine (hmdU).

159 , slowly cycling cells by tracking 5-iodo-2'-deoxyuridine (IdU) label-retaining cells (LRCs) in norma

160 ts into the pathogenic role of thymidine and deoxyuridine imbalance in mitochondrial neurogastrointes

161 (Kd = 0.20 nm) modified at the 5-position of deoxyuridine in a complex with IL-6.

162 ysis of the N-glycosidic bond, converting 2'-deoxyuridine in DNA to an abasic site, was continuously

163 etoglutarate/O(2)-dependent hydroxylation of deoxyuridine in fungal extracts have been reported previ

164 of the pyrimidine nucleosides thymidine and deoxyuridine in plasma and tissues, and somatic multiple

165 nase that converts deoxycytidine residues to deoxyuridine in single-stranded DNA (ssDNA).

166 evere TP deficiency, increased thymidine and deoxyuridine in tissues and elevated mitochondrial deoxy

167 activity deficiency, elevated thymidine and deoxyuridine in tissues, mitochondrial DNA depletion, re

168 Incorporation of 5-bromo-2-deoxyuridine in vivo increased in neurogenic areas in ad

169 inates deoxycytidine nucleotides, generating deoxyuridine, in single stranded DNA (ssDNA) intermediat

170 cell DNA synthesis by detection of 5-bromo-2-deoxyuridine incorporated into the nuclei of crypt cells

171 transcription factor Fli1 were generated by deoxyuridine incorporation and endonuclease V cleavage.

172 m progenitor cells were detected using bromo-deoxyuridine incorporation and Ki67 immunostaining.

173 crease but not complete elimination of bromo-deoxyuridine incorporation and mitoses at 24 hours after

174 5-ethynyl-2'-deoxyuridine and 5-bromo-2'-deoxyuridine incorporation assays were used to study pat

175 sing fluorescence microscopy of 5-ethynyl-2'-deoxyuridine incorporation in fixed cells.

176 al protein S6 phosphorylation and 5-bromo-2'-deoxyuridine incorporation in wild-type but not CB(2) re

177 s of cell-cycle progression and 5-ethynyl-2'-deoxyuridine incorporation through flow cytometry reveal

178 5-Bromo-2'-deoxyuridine incorporation was 25% in LPG but only 5% in

179 Proliferation was measured by 5-bromo-2'-deoxyuridine incorporation, [(3)H]thymidine incorporatio

180 proliferation was evaluated with 5-bromo-2'-deoxyuridine incorporation, and cell size assessed by fl

181 estigated by morphometric analysis, bromo-2'-deoxyuridine incorporation, and immunostaining.

182 trombopag neither led to increased 5-bromo-2-deoxyuridine incorporation, decreased apoptosis, an incr

183 -associated beta-galactosidase and 5-bromo-2-deoxyuridine incorporation, in normal but not cancerous

184 tor) treatments, as determined by 5-bromo-2'-deoxyuridine incorporation, Ki-67 staining and clonogeni

185 5-Bromo-2'-deoxyuridine incorporation, proliferating cell nuclear a

186 e-treated cells as determined by 5'-bromo-2'-deoxyuridine incorporation.

187 heir proliferation as measured by 5-bromo-2'-deoxyuridine incorporation.

188 ll cycle transition and decreases 5-bromo-2'-deoxyuridine incorporation.

189 Proliferation was quantified by 5-bromo-2'-deoxyuridine incorporation.

190 f the cell cycle, decreased BrdU (5-bromo-2'-deoxyuridine) incorporation, and led to increased expres

191 tion of 5-chloro-2-deoxyuridine and 5-iodo-2-deoxyuridine indicated that all HSCs segregate their chr

192 The 5-bromo-2'-deoxyuridine injections were administered every 3 days t

193 ectrophysiological measures; BrdU (5-bromo-2-deoxyuridine) injections were used to quantify cell surv

194 modified nucleotides such as 5-N-carboxamide-deoxyuridines into random nucleic acid libraries improve

195 Because click labeling with 5-ethynyl-2'-deoxyuridine is hampered by intense background staining

196 ith 5-azacytidine (AzaC) and with 5'-iodo-2'-deoxyuridine (IUdR); none was detected with sodium butyr

197 use a massive dispersion of BrdU (5-bromo-2'-deoxyuridine)-labeled neuroblasts into surrounding brain

198 1/2-, nuclear beta-catenin-, and 5-bromo-2'-deoxyuridine-labeled cells and altered keratin (K) 14 (K

199 n increase in the percentage of 5-ethynyl-2'-deoxyuridine-labeled myocytes.

200 273H and R248W bound to nascent 5-ethynyl-2'-deoxyuridine-labeled replicating DNA.

201 5-Bromo-2'-deoxyuridine labeling and increases of graft weight were

202 5-Bromo-2'-deoxyuridine labeling reveals that cyst-lining epithelia

203 nvestigated if MUC1 regulated ER stress by a deoxyuridine-mediated modulation of ROS levels.

204 DA activity corresponded to deoxycytidine to deoxyuridine metabolic reprogramming upon ER stress indu

205 The resulting increase in deoxyuridine mitigated ER stress-induced cytotoxicity.

206 was successfully detected and quantified by deoxyuridine-modified DNAzymes that underwent UNG-depend

207 logue, 5-(1-phenyl-1H-1,2,3-triazol-4-yl)-2'-deoxyuridine monomer W in oligonucleotides, has demonstr

208 published 5-(1-phenyl-1,2,3-triazol-4-yl)-2'-deoxyuridine monomer W.

209 at is the 5-(4-phenyl-1,2,3-triazol-1-yl)-2'-deoxyuridine monomer Y, was found to destabilize the DNA

210 Finally, the 5-phenyl-2'-deoxyuridine monomer Z was incorporated for comparison,

211 s the production of the nucleotide dTMP from deoxyuridine monophosphate (dUMP), making the enzyme nec

212 man enzyme (hTMPK) and to the utilization of deoxyuridine monophosphate (dUMP)/deoxy-5-fluorouridine

213 ns that prevents the stable incorporation of deoxyuridine monophosphate into DNA in the form of U/A b

214 ected DNA fragments containing a 5'-terminal deoxyuridine monophosphate.

215 nd decreased the number of BrdU+ (5-bromo-2'-deoxyuridine+) myocytes detected at the infarct border z

216 U) or 5-[N-(1-naphthylmethyl)carboxamide]-2'-deoxyuridine (Nap-dU) replacing dT.

217 dine-positive (or Ki67(+) ) and 5-ethynyl-2'-deoxyuridine-negative (Ki67(-) ) cells was inversely rel

218 paired posttraumatic neurogenesis (5-bromo-2-deoxyuridine + NeuN-positive cells).

219 peptide and a ureido linkage as well as a 3'-deoxyuridine nucleoside attached to DABA(3) of the pepti

220 Three 5-modified 2'-deoxyuridine nucleosides were synthesized and incorporat

221 n rate was analyzed measuring the 5-bromo-2'-deoxyuridine nucleotide uptake.

222 pe 1 virions and deaminates deoxycytidine to deoxyuridine on nascent minus-strand retroviral cDNA, le

223 anine) were attached to the 5-position of 2'-deoxyuridine or 2'-deoxycytidine through a propyne linke

224 uridine inhibited its isomerization while 2'-deoxyuridine or 4-thiouridine did not.

225 o, unless supplemented with uracil, uridine, deoxyuridine or UMP.

226 idine phosphorylase treated with 5-fluoro-2'-deoxyuridine or uridine, plus sulfate.

227 rmanes gave (Z)-5-(2-germylvinyl)uridine, 2'-deoxyuridine, or ara-uridine as major products.

228 n complex with uracil/ribose-1-phosphate, 2'-deoxyuridine/phosphate and thymidine/phosphate were anal

229 eloped protocols for 2'-N-methyl-2'-amino-2'-deoxyuridine phosphoramidites that are functionalized at

230 C2'-pyrene-functionalized triazole-linked 2'-deoxyuridine phosphoramidites.

231 e aminotransferase; (ii) LipP, a 5'-amino-5'-deoxyuridine phosphorylase; (iii) LipM, a UTP:5-amino-5-

232 significant dose-dependent decrease in bromo-deoxyuridine positive cells was observed.

233 uronal injury and neurogeneration (5-bromo-2-deoxyuridine positive neurons) were quantified on day 7

234 -independent as killing of both 5-ethynyl-2'-deoxyuridine-positive (or Ki67(+) ) and 5-ethynyl-2'-deo

235 roliferation with decreased numbers of bromo-deoxyuridine-positive cells following ketamine exposure

236 In addition, there were fewer 5-bromo-2'-deoxyuridine-positive cells in the LK population in Chd7

237 MA also induced a 33% decrease in 5-bromo-2'-deoxyuridine-positive CFs, which was inhibited with Go69

238 a combination of immunostaining, 5-bromo-2'-deoxyuridine proliferation assays, and histologic staini

239 The 5-ethynyl-2'-deoxyuridine pulse-chase experiments further reveal that

240 T2.1 in the 8-17 DNAzyme was replaced with a deoxyuridine, resulting in minimal change of the DNAzyme

241 We support this model by 5-ethynyl-2'-deoxyuridine retention experiments in shoot and root api

242 ell nuclear antigen, cyclin A, and 5-bromo-2-deoxyuridine reveals that cyclin E promotes progression

243 nt mice treated with exogenous thymidine and deoxyuridine showed reduced survival, body weight, and m

244 Cell cycle tracking using 5-ethynyl-2'-deoxyuridine staining and fluorescent cell cycle markers

245 Green fluorescent protein and 5-bromo-2'-deoxyuridine staining indicated that persistence of dono

246 According to 5-ethynyl-2'-deoxyuridine staining, few cells (1%) actively cycled un

247 erized by flow cytometry and BrdU (5-bromo-2-deoxyuridine) staining following synchronization of cult

248 ive cells also were costained for 5-bromo-2'-deoxyuridine, suggesting their re-entry into the cell cy

249 Maternal deoxyuridine supplementation prevented NTDs in dams fed

250 lower yields of products such as 5-formyl-2'-deoxyuridine that are ascribable to deprotonation from t

251 Four triphosphates of 2'-deoxyuridine that carried the following bioorthogonally

252 molecules is the biosynthetically unique 3'-deoxyuridine that they share.

253 thylene linkers, or to the 2'-position of 2'-deoxyuridine through a more rigid triazole linker.

254 ion of thymidine or to the 2'-position of 2'-deoxyuridine through triazolemethylene linkers, or to th

255 dine to uracil and ribose 1-phosphate (or 2'-deoxyuridine to 2'-deoxyribose 1-phosphate).

256 ction and used the mitotic marker 5-bromo-2'-deoxyuridine to analyze adult neurogenesis.

257 dditionally, mice were provided 5-ethynyl-2'-deoxyuridine to determine satellite cell proliferation,

258 reversible phosphorolysis of uridine and 2'-deoxyuridine to generate uracil and (2-deoxy)ribose 1-ph

259 ch repair factor MSH2/MSH6, must process the deoxyuridine to initiate class-switch recombination (CSR

260 Using the thymidine analog 5-ethynyl-2'-deoxyuridine to monitor DNA replication of cells of Arab

261 In another design, introducing a deoxyuridine to the 3' position of the deoxycytidine C13

262 identified the folate pathway-related genes, deoxyuridine triphosphatase and dihydrofolate reductase,

263 is terminator is based on 5-hydroxymethyl-2'-deoxyuridine triphosphate (HOMedUTP), a hypermodified nu

264 ive analogs against other metabolites (e.g., deoxyuridine triphosphate and l-2-hydroxyglutarate).

265 A deoxyuridine triphosphate derivative carrying a diene at

266 rminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate nick end labeling assay.

267 erminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick end-labeling (TUNEL)-posi

268 erminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick end-labeling, and caspase

269 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) hist

270 ypothermia also reduced transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL)(+) n

271 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL).

272 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling analyses.

273 erminal deoxynucleotide transferase-mediated deoxyuridine triphosphate nick-end labeling and caspase-

274 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling, Notch-1, an

275 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling-positive nuc

276 trated that Epstein-Barr virus (EBV)-encoded deoxyuridine triphosphate nucleotidohydrolase (dUTPase)

277 ecent haplotype analyses have suggested that deoxyuridine triphosphate nucleotidohydrolase (dUTPase)

278 Deoxyuridine triphosphate nucleotidohydrolase (dUTPase)

279 the relation between an early viral protein, deoxyuridine triphosphate nucleotidohydrolase (dUTPase),

280 (PAEC) to apoptosis was increased by HERV-K deoxyuridine triphosphate nucleotidohydrolase in an inte

281 Furthermore, 3 weekly injections of HERV-K deoxyuridine triphosphate nucleotidohydrolase induced he

282 HERV-K deoxyuridine triphosphate nucleotidohydrolase induced SA

283 HERV-K envelope and deoxyuridine triphosphate nucleotidohydrolase mRNAs were

284 mmunohistochemistry and Transferase-mediated deoxyuridine triphosphate-biotin nick end labelling (TUN

285 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labeling (TUNE

286 rminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labeling analy

287 labeling using the cyclopropene-modified 2'-deoxyuridine triphosphate.

288 he dephosphorysynthase pathway that includes deoxyuridine triphosphatelation of [(3)H]TMP to [(3)H]th

289 egakaryocytes exhibiting enhanced 5-bromo-2'-deoxyuridine uptake and increased expression of messenge

290 oliferation as indicated by lower 5-bromo-2'-deoxyuridine uptake, increased apoptosis, and reduced ex

291 less cytostatic metabolite 2',2'-difluoro-2'-deoxyuridine was observed, both in cell extracts and spe

292 A 1-h pulse of the nucleotide 5-ethynyl-2'-deoxyuridine was sufficient to label 5% of DCs in both l

293 Tetraphenyl porphyrin substituted deoxyuridine was used as a building block to create disc

294 nd (3) the emerging anti-oxidant property of deoxyuridine, we further investigated if MUC1 regulated

295 and supplemented with uridine, thymidine, or deoxyuridine were bred, and litters (n = 10-23 per group

296 ycytidine residues in single-stranded DNA to deoxyuridines, which are then processed by DNA replicati

297 yrimidine nucleosides uridine, thymidine, or deoxyuridine with and without folate deficiency on NTD i

298 D) catalyses deamination of deoxycytidine to deoxyuridine within immunoglobulin loci, triggering path

299 ugar-protected 6-cyanouridine and 6-cyano-2'-deoxyuridine without the protection at the N(3)-imide an

300 e-specific insertion of 5-(3-aminopropyl)-2'-deoxyuridine (Z3dU) and 7-deaza-dG into the Dickerson-Dr